Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis.
暂无分享,去创建一个
E. Antman | E. Braunwald | C. McCabe | E. Braunwald | M. Cohen | D. Radley | J. Rush | J. Premmereur | C. Mccabe | C. Mccabe
[1] E. Antman,et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. , 1999, Circulation.
[2] Organisation to Assess Strategies for Ischemic Syndromes Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial , 1999, The Lancet.
[3] L. Wallentin. New antithrombotic treatment in unstable coronary syndrome—for whom? , 1999, The Lancet.
[4] M. Milling,et al. molecular weight heparins , 1999 .
[5] F. Verheugt. Hotline sessions at the 20th European Congress of Cardiology. , 1999, European heart journal.
[6] A. Haeberli,et al. Effect of intravenous heparin infusion on thrombin-antithrombin complex and fibrinopeptide A in unstable angina. , 1998, American heart journal.
[7] C. Ballantyne. Low-density lipoproteins and risk for coronary artery disease. , 1998, The American journal of cardiology.
[8] D. Hoppensteadt,et al. Low-molecular-weight heparins: pharmacologic profile and product differentiation. , 1998, The American journal of cardiology.
[9] E. Antman,et al. Rationale for the management of coronary syndromes with low-molecular-weight heparins. , 1998, The American journal of cardiology.
[10] E. Vicaut,et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. , 1998, Circulation.
[11] E. Antman,et al. Low-molecular-weight heparins: an intriguing new twist with profound implications. , 1998, Circulation.
[12] R. Califf,et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarc , 1998, Circulation.
[13] H. Ostermann. Low molecular weight heparins , 1998, Der Internist.
[14] Marc Cohen,et al. One Year Follow-up of the ESSENCE Trial (enoxaparin Versus Heparin in Unstable Angina and Non-Q-Wave Myocardial Infarction) , 1998 .
[15] P Théroux,et al. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. , 1998, Circulation.
[16] D. Hunt. Low-molecular-weight Heparins in Clinical Practice , 1998, Southern medical journal.
[17] L. Wallentin,et al. Low-Molecular-Weight Heparin (Fragmin) During Instability in Coronary Artery Disease (FRISC) , 1997 .
[18] J. Nunnelee. Low-molecular-weight heparin. , 1997, Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing.
[19] R. Califf,et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. , 1997 .
[20] W. Klein,et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC) , 1997, Circulation.
[21] J. Clinton. Agency for Health Care Policy and Research. , 1997, Asian American and Pacific Islander journal of health.
[22] M. Whooley,et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. , 1997, JAMA.
[23] V. Fuster,et al. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial. , 1996, Circulation.
[24] E. Antman. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. , 1996, Circulation.
[25] J. Shah,et al. Management of Barrett's oesophagus , 1996, The Lancet.
[26] D. Brieger,et al. Long Term Persistence of Biological Activity following Administration of Enoxaparin Sodium (Clexane) Is due to Sequestration of Antithrombin-binding Low Molecular Weight Fragments - Comparison with Unfractionated Heparin , 1996, Thrombosis and Haemostasis.
[27] K. Wiklund,et al. Low-molecular-weight heparin during instability in coronary artery disease , 1996 .
[28] G. Agnelli. Pharmacological activities of heparin chains: should our past knowledge be revised? , 1996, Haemostasis.
[29] M. Simoons. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. , 1996, The New England journal of medicine.
[30] D. Hoppensteadt,et al. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low‐molecular‐weight heparin , 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[31] L. Wilkins. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. , 1994, Circulation.
[32] U. Tebbe,et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK) , 1994, Circulation.
[33] E. Antman. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. , 1994, Circulation.
[34] Daniel B. Mark,et al. Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. , 1994, Circulation.
[35] V. Fuster,et al. Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association. , 1994, Circulation.
[36] Walker,et al. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .
[37] E. Braunwald. Unstable angina : diagnosis and management , 1994 .
[38] H. Bounameaux. Low-molecular-weight heparins in prophylaxis and therapy of thromboembolic diseases , 1994 .
[39] R. Kronmal,et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. , 1994, Circulation.
[40] J. Hirsh,et al. Comparison of the Non-Specific Binding of Unfractionated Heparin and Low Molecular Weight Heparin (Enoxaparin) to Plasma Proteins , 1993, Thrombosis and Haemostasis.
[41] S. Nightingale. Appropriate Use of Low-Molecular-Weight Heparins (LMWHs) , 1993 .
[42] J. Hirsh. Low Molecular Weight Heparin , 1993, Thrombosis and Haemostasis.
[43] T C Chalmers,et al. Cumulative meta-analysis of therapeutic trials for myocardial infarction. , 1992, The New England journal of medicine.
[44] D. Waters,et al. Reactivation of unstable angina after the discontinuation of heparin. , 1992, The New England journal of medicine.
[45] H. Hemker,et al. Anticoagulant mechanism of action of low molecular weight heparins , 1992 .
[46] C. Madden. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease: The RISC Group Lancet 336: 827–830 Oct 1990 , 1991 .
[47] A. Lindahl,et al. Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood. , 1991, Haemostasis.
[48] The Risc Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease , 1990, The Lancet.
[49] S Greenland,et al. Bias in the one-step method for pooling study results. , 1990, Statistics in medicine.
[50] H. Hemker,et al. The Mode of Action of Low Molecular Weight Heparin Preparation (PK10169) and Two of its Major Components on Thrombin Generation in Plasma , 1989, Thrombosis and Haemostasis.
[51] T C Chalmers,et al. A comparison of statistical methods for combining event rates from clinical trials. , 1989, Statistics in medicine.
[52] J. Cairns,et al. Antithrombotic agents in coronary artery disease. , 1989, Chest.
[53] Aspirin, heparin, or both to treat unstable angina. , 1989, The New England journal of medicine.
[54] H. Hemker,et al. The Mode of Action of Heparin in Plasma , 1988, Thrombosis and Haemostasis.
[55] P. Théroux,et al. Aspirin, heparin, or both to treat acute unstable angina. , 1988, The New England journal of medicine.
[56] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[57] N Breslow,et al. Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models. , 1986, Biometrics.
[58] D. Lane,et al. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. , 1984, The Biochemical journal.
[59] A. Telford,et al. TRIAL OF HEPARIN VERSUS ATENOLOL IN PREVENTION OF MYOCARDIAL INFARCTION IN INTERMEDIATE CORONARY SYNDROME , 1981, The Lancet.